TARS Tarsus Pharmaceuticals Inc
Price (delayed)
$51.49
Market cap
$1.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$1.95B
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline
Highlights
The company's revenue rose by 41% QoQ
Tarsus Pharmaceuticals's gross profit has increased by 41% from the previous quarter
The company's equity rose by 14% YoY but it fell by 5% QoQ
Tarsus Pharmaceuticals's debt has surged by 141% YoY
The company's quick ratio fell by 37% YoY and by 20% QoQ
Key stats
What are the main financial stats of TARS
Market
Valuations
Earnings
Shares outstanding
38.38M
Market cap
$1.98B
Enterprise value
$1.95B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.77
Price to sales (P/S)
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.68
Revenue
$182.95M
Gross profit
$170.13M
Operating income
-$120.57M
Net income
-$115.55M
EBIT
-$107.71M
EBITDA
-$105.85M
Free cash flow
-$89.59M
Per share
Balance sheet
Liquidity
EPS
-$3.07
EPS diluted
-$3.07
Free cash flow per share
-$2.38
Book value per share
$5.87
Revenue per share
$4.87
TBVPS
$9.8
Total assets
$376.99M
Total liabilities
$152.46M
Debt
$71.85M
Equity
$224.53M
Working capital
$276.09M
Debt to equity
0.32
Current ratio
4.42
Quick ratio
4.21
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-57.9%
Gross margin
93%
Net margin
-63.2%
Operating margin
-65.9%
Return on assets
-31.2%
Return on equity
-46.7%
Return on invested capital
-52.9%
Return on capital employed
-36.3%
Return on sales
-58.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARS stock price
How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
5.25%
1 week
0.94%
1 month
15.76%
1 year
44.72%
YTD
-7.01%
QTD
0.23%
Financial performance
How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$182.95M
Gross profit
$170.13M
Operating income
-$120.57M
Net income
-$115.55M
Gross margin
93%
Net margin
-63.2%
Tarsus Pharmaceuticals's operating margin has soared by 92% YoY and by 39% from the previous quarter
Tarsus Pharmaceuticals's net margin has surged by 92% YoY and by 39% QoQ
The company's revenue rose by 41% QoQ
Tarsus Pharmaceuticals's gross profit has increased by 41% from the previous quarter
Growth
What is Tarsus Pharmaceuticals's growth rate over time
Valuation
What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.77
P/S
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.68
The company's EPS rose by 34% YoY and by 19% QoQ
TARS's P/B is 138% above its 5-year quarterly average of 3.5 and 44% above its last 4 quarters average of 5.8
The company's equity rose by 14% YoY but it fell by 5% QoQ
The P/S is 48% lower than the 5-year quarterly average of 19.4 and 37% lower than the last 4 quarters average of 15.9
The company's revenue rose by 41% QoQ
Efficiency
How efficient is Tarsus Pharmaceuticals business performance
The company's return on sales has surged by 92% YoY and by 40% QoQ
TARS's return on invested capital has surged by 68% year-on-year and by 40% since the previous quarter
The ROA has grown by 46% YoY and by 21% from the previous quarter
TARS's ROE is up by 37% YoY and by 16% from the previous quarter
Dividends
What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARS.
Financial health
How did Tarsus Pharmaceuticals financials performed over time
TARS's total assets is 147% greater than its total liabilities
Tarsus Pharmaceuticals's total liabilities has soared by 123% YoY and by 10% from the previous quarter
TARS's total assets is up by 42% year-on-year
Tarsus Pharmaceuticals's debt is 68% lower than its equity
Tarsus Pharmaceuticals's debt has surged by 141% YoY
The debt to equity has soared by 113% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.